Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

Source link :

TOPLINE: Belantamab mafodotin plus a combination of bortezomib and dexamethasone improved median progression-free survival (PFS) by 23 months in patients with relapsed or refractory multiple myeloma compared with daratumumab alongside the same combination. METHODOLOGY: Patients with multiple myeloma who relapse often become refractory to frontline triplet or quadruplet regimens and need effective second-line options. The […]

Author : News Health

Publish date : 2024-02-09 05:02:48

Copyright for syndicated content belongs to the linked Source.